Digest Network How does it work
Network
/
Society
IL
Not verified

ILiAD Biotechnologies, Inc.

What we write about

BiotechnologyHealthHIV, AIDS and autoimmune disordersIndustriaPharmaceuticals

6 Press releases

View all press releases
03/10/2026
Industria
Biotechnology
Books / Publishing
Medical and health
Sanità
Health
HIV, AIDS and autoimmune disorders
Communication
ILiAD Biotechnologies amplia il potenziale di BPZE1 per la salute pubblica e commerciale con la pubblicazione dello studio di Fase 2b nella rivista The Lancet Infectious Diseases
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0
02/10/2026
Industria
Biotechnology
Books / Publishing
Medical and health
Sanità
Health
HIV, AIDS and autoimmune disorders
Communication
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0
11/08/2026
Labour market
Health
HIV, AIDS and autoimmune disorders
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
ILiAD Biotechnologies amplia il CdA con la nomina del Direttore finanziario
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0
11/08/2026
Labour market
Health
HIV, AIDS and autoimmune disorders
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0
10/02/2026
Industria
Scienza
Biotechnology
Pharmaceuticals
Finance
Health
HIV, AIDS and autoimmune disorders
Associations / Professional
ILiAD Biotechnologies annuncia di aver ottenuto un finanziamento di serie B del valore di 115 milioni di dollari (con eccesso di sottoscrizioni) per promuovere il vaccino antipertosse BPZE1
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0
10/02/2026
Scienza
Biotechnology
Pharmaceuticals
Finance
Health
HIV, AIDS and autoimmune disorders
Associations / Professional
Industria
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine
Source
ILiAD Biotechnologies, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0